Galectins: emerging regulatory checkpoints linking tumor immunity and angiogenesis
Immune checkpoints, a plethora of inhibitory pathways aimed at maintaining immune cell homeostasis, may be co-opted by cancer cells to evade immune destruction. Therapies targeting immune checkpoints have reached a momentum yielding significant clinical benefits in patients with various malignancies...
Guardado en:
| Autores principales: | , , |
|---|---|
| Formato: | JOUR |
| Materias: | |
| Acceso en línea: | http://hdl.handle.net/20.500.12110/paper_09527915_v45_n_p8_MendezHuergo |
| Aporte de: |
| id |
todo:paper_09527915_v45_n_p8_MendezHuergo |
|---|---|
| record_format |
dspace |
| spelling |
todo:paper_09527915_v45_n_p8_MendezHuergo2023-10-03T15:50:46Z Galectins: emerging regulatory checkpoints linking tumor immunity and angiogenesis Méndez-Huergo, S.P. Blidner, A.G. Rabinovich, G.A. galectin glycan galectin bone marrow cell carcinogenesis CD4+ T lymphocyte cell differentiation gene expression profiling glioblastoma glycosylation human immunomodulation immunoregulation internalization Kaposi sarcoma natural killer cell oligomerization protein binding protein domain protein protein interaction regulatory T lymphocyte Review signal transduction T lymphocyte tumor associated leukocyte tumor immunity animal immunology neoplasm neovascularization (pathology) pathology vascularization Animals Galectins Humans Killer Cells, Natural Neoplasms Neovascularization, Pathologic T-Lymphocytes Immune checkpoints, a plethora of inhibitory pathways aimed at maintaining immune cell homeostasis, may be co-opted by cancer cells to evade immune destruction. Therapies targeting immune checkpoints have reached a momentum yielding significant clinical benefits in patients with various malignancies by unleashing anti-tumor immunity. Galectins, a family of glycan-binding proteins, have emerged as novel regulatory checkpoints that promote immune evasive programs by inducing T-cell exhaustion, limiting T-cell survival, favoring expansion of regulatory T cells, de-activating natural killer cells and polarizing myeloid cells toward an immunosuppressive phenotype. Concomitantly, galectins can trigger vascular signaling programs, serving as bifunctional messengers that couple tumor immunity and angiogenesis. Thus, targeting galectin–glycan interactions may halt tumor progression by simultaneously augmenting antitumor immunity and suppressing aberrant angiogenesis. © 2017 Elsevier Ltd JOUR info:eu-repo/semantics/openAccess http://creativecommons.org/licenses/by/2.5/ar http://hdl.handle.net/20.500.12110/paper_09527915_v45_n_p8_MendezHuergo |
| institution |
Universidad de Buenos Aires |
| institution_str |
I-28 |
| repository_str |
R-134 |
| collection |
Biblioteca Digital - Facultad de Ciencias Exactas y Naturales (UBA) |
| topic |
galectin glycan galectin bone marrow cell carcinogenesis CD4+ T lymphocyte cell differentiation gene expression profiling glioblastoma glycosylation human immunomodulation immunoregulation internalization Kaposi sarcoma natural killer cell oligomerization protein binding protein domain protein protein interaction regulatory T lymphocyte Review signal transduction T lymphocyte tumor associated leukocyte tumor immunity animal immunology neoplasm neovascularization (pathology) pathology vascularization Animals Galectins Humans Killer Cells, Natural Neoplasms Neovascularization, Pathologic T-Lymphocytes |
| spellingShingle |
galectin glycan galectin bone marrow cell carcinogenesis CD4+ T lymphocyte cell differentiation gene expression profiling glioblastoma glycosylation human immunomodulation immunoregulation internalization Kaposi sarcoma natural killer cell oligomerization protein binding protein domain protein protein interaction regulatory T lymphocyte Review signal transduction T lymphocyte tumor associated leukocyte tumor immunity animal immunology neoplasm neovascularization (pathology) pathology vascularization Animals Galectins Humans Killer Cells, Natural Neoplasms Neovascularization, Pathologic T-Lymphocytes Méndez-Huergo, S.P. Blidner, A.G. Rabinovich, G.A. Galectins: emerging regulatory checkpoints linking tumor immunity and angiogenesis |
| topic_facet |
galectin glycan galectin bone marrow cell carcinogenesis CD4+ T lymphocyte cell differentiation gene expression profiling glioblastoma glycosylation human immunomodulation immunoregulation internalization Kaposi sarcoma natural killer cell oligomerization protein binding protein domain protein protein interaction regulatory T lymphocyte Review signal transduction T lymphocyte tumor associated leukocyte tumor immunity animal immunology neoplasm neovascularization (pathology) pathology vascularization Animals Galectins Humans Killer Cells, Natural Neoplasms Neovascularization, Pathologic T-Lymphocytes |
| description |
Immune checkpoints, a plethora of inhibitory pathways aimed at maintaining immune cell homeostasis, may be co-opted by cancer cells to evade immune destruction. Therapies targeting immune checkpoints have reached a momentum yielding significant clinical benefits in patients with various malignancies by unleashing anti-tumor immunity. Galectins, a family of glycan-binding proteins, have emerged as novel regulatory checkpoints that promote immune evasive programs by inducing T-cell exhaustion, limiting T-cell survival, favoring expansion of regulatory T cells, de-activating natural killer cells and polarizing myeloid cells toward an immunosuppressive phenotype. Concomitantly, galectins can trigger vascular signaling programs, serving as bifunctional messengers that couple tumor immunity and angiogenesis. Thus, targeting galectin–glycan interactions may halt tumor progression by simultaneously augmenting antitumor immunity and suppressing aberrant angiogenesis. © 2017 Elsevier Ltd |
| format |
JOUR |
| author |
Méndez-Huergo, S.P. Blidner, A.G. Rabinovich, G.A. |
| author_facet |
Méndez-Huergo, S.P. Blidner, A.G. Rabinovich, G.A. |
| author_sort |
Méndez-Huergo, S.P. |
| title |
Galectins: emerging regulatory checkpoints linking tumor immunity and angiogenesis |
| title_short |
Galectins: emerging regulatory checkpoints linking tumor immunity and angiogenesis |
| title_full |
Galectins: emerging regulatory checkpoints linking tumor immunity and angiogenesis |
| title_fullStr |
Galectins: emerging regulatory checkpoints linking tumor immunity and angiogenesis |
| title_full_unstemmed |
Galectins: emerging regulatory checkpoints linking tumor immunity and angiogenesis |
| title_sort |
galectins: emerging regulatory checkpoints linking tumor immunity and angiogenesis |
| url |
http://hdl.handle.net/20.500.12110/paper_09527915_v45_n_p8_MendezHuergo |
| work_keys_str_mv |
AT mendezhuergosp galectinsemergingregulatorycheckpointslinkingtumorimmunityandangiogenesis AT blidnerag galectinsemergingregulatorycheckpointslinkingtumorimmunityandangiogenesis AT rabinovichga galectinsemergingregulatorycheckpointslinkingtumorimmunityandangiogenesis |
| _version_ |
1807315749080924160 |